Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives | SeamlessBio<\/title>\n\n<style>\n:root {\n --teal: #18b7b2; --teal-dark: #139b97; --teal-pale: #e9fbfa;\n --dark: #1a2e35; --mid: #2e4a54; --grey: #f4f6f7;\n --border: #d8e8e7; --text: #2c3e3f; --muted: #6b7f82;\n --white: #ffffff; --orange: #e07b00; --green: #1a7f4b;\n}\n*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\nbody { font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 16px; line-height: 1.7; color: var(--text); background: var(--white); max-width: 1100px; margin: 0 auto; padding: 0 20px; }\nh1 { font-size: 32px; font-weight: 800; color: var(--dark); line-height: 1.2; }\nh2 { font-size: 22px; font-weight: 700; color: var(--dark); margin: 48px 0 16px; padding-bottom: 8px; border-bottom: 2px solid var(--teal); }\nh3 { font-size: 17px; font-weight: 700; color: var(--dark); margin: 24px 0 10px; }\np { margin-bottom: 14px; }\na { color: var(--teal-dark); text-decoration: none; }\na:hover { text-decoration: underline; }\nul, ol { padding-left: 20px; margin-bottom: 14px; }\nli { margin-bottom: 6px; }\nstrong { color: var(--dark); }\n\n\/* Hero *\/\n.hero { background: linear-gradient(135deg, #18b7b2 0%, #62d0cc 60%, #a8e6e4 100%); border-radius: 16px; padding: 48px 40px; margin: 32px 0 40px; display: grid; grid-template-columns: 1fr 200px; gap: 32px; align-items: center; }\n.hero .eyebrow { display: inline-block; font-size: 11px; font-weight: 700; letter-spacing: 1.5px; text-transform: uppercase; color: rgba(255,255,255,0.9); background: rgba(0,0,0,0.15); border-radius: 20px; padding: 4px 14px; margin-bottom: 16px; }\n.hero h1 { color: var(--white); font-size: 28px; text-shadow: 0 1px 3px rgba(0,0,0,0.25); margin-bottom: 12px; }\n.hero .lead { font-size: 16px; color: rgba(255,255,255,0.95); line-height: 1.6; text-shadow: 0 1px 2px rgba(0,0,0,0.2); margin: 0 0 20px; }\n.hero-tags { display: flex; flex-wrap: wrap; gap: 8px; }\n.tag { background: rgba(0,0,0,0.15); border: 1px solid rgba(255,255,255,0.3); color: var(--white); font-size: 12px; font-weight: 600; padding: 4px 12px; border-radius: 20px; }\n.hero-right { display: flex; flex-direction: column; gap: 16px; }\n.hero-stat { background: rgba(0,0,0,0.15); border-radius: 12px; padding: 20px; text-align: center; color: var(--white); }\n.hero-stat .stat-num { font-size: 28px; font-weight: 700; line-height: 1; }\n.hero-stat .stat-label { font-size: 12px; color: rgba(255,255,255,0.85); margin-top: 6px; }\n\n\/* Quick Answer *\/\n.quick-answer { background: var(--teal-pale); border-left: 4px solid var(--teal); border-radius: 0 8px 8px 0; padding: 20px 24px; margin: 0 0 40px; }\n.quick-answer .qa-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--teal-dark); margin-bottom: 8px; }\n.quick-answer p { margin: 0; font-size: 15px; }\n\n\/* TOC *\/\n.toc { background: var(--grey); border-radius: 8px; padding: 20px 24px; margin-bottom: 40px; }\n.toc h4 { font-size: 13px; text-transform: uppercase; letter-spacing: 1px; color: var(--muted); margin-bottom: 12px; }\n.toc ol { margin: 0; padding-left: 18px; }\n.toc li { font-size: 14px; margin-bottom: 4px; }\n\n\/* Decision matrix *\/\n.decision-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 16px; margin: 20px 0 32px; }\n.decision-card { border-radius: 10px; padding: 20px 22px; }\n.decision-card.go { background: #f0fdf4; border: 1px solid #86efac; border-left: 4px solid var(--green); }\n.decision-card.slow { background: #fff8e6; border: 1px solid #fcd34d; border-left: 4px solid var(--orange); }\n.decision-card.no { background: #fef2f2; border: 1px solid #fca5a5; border-left: 4px solid #dc2626; }\n.decision-card .dc-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 8px; }\n.decision-card.go .dc-label { color: var(--green); }\n.decision-card.slow .dc-label { color: var(--orange); }\n.decision-card.no .dc-label { color: #dc2626; }\n.decision-card h3 { font-size: 15px; margin: 0 0 8px; }\n.decision-card ul { font-size: 14px; margin: 0; color: var(--text); }\n\n\/* Steps *\/\n.steps { counter-reset: step; }\n.step { display: flex; gap: 20px; margin-bottom: 16px; padding: 20px 24px; background: var(--grey); border-radius: 8px; align-items: flex-start; }\n.step-num { counter-increment: step; min-width: 36px; height: 36px; background: var(--teal); color: var(--white); border-radius: 50%; display: flex; align-items: center; justify-content: center; font-weight: 700; font-size: 15px; flex-shrink: 0; }\n.step-num::before { content: counter(step); }\n.step-body h3 { margin: 0 0 6px; font-size: 16px; }\n.step-body p { margin: 0; font-size: 15px; }\n\n\/* Alternative cards *\/\n.alt-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(260px, 1fr)); gap: 20px; margin: 20px 0 32px; }\n.alt-card { border: 1px solid var(--border); border-radius: 12px; padding: 22px 24px; background: var(--white); }\n.alt-card .alt-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--teal-dark); margin-bottom: 8px; }\n.alt-card h3 { font-size: 16px; margin: 0 0 10px; }\n.alt-card p { font-size: 14px; color: var(--muted); margin: 0 0 10px; }\n.alt-card .alt-conc { font-size: 13px; font-weight: 700; color: var(--dark); padding: 4px 10px; background: var(--grey); border-radius: 4px; display: inline-block; margin-bottom: 12px; }\n.alt-card a { font-size: 13px; font-weight: 700; color: var(--teal-dark); }\n\n\/* Comparison table *\/\n.spec-table { width: 100%; border-collapse: collapse; margin: 16px 0 24px; font-size: 15px; }\n.spec-table th { background: var(--dark); color: var(--white); padding: 10px 14px; text-align: left; font-size: 13px; font-weight: 600; }\n.spec-table td { padding: 10px 14px; border-bottom: 1px solid var(--border); vertical-align: top; }\n.spec-table tr:nth-child(even) td { background: var(--grey); }\n\n\/* Note \/ pro-serum box *\/\n.note-box { background: #fff8e6; border-left: 4px solid var(--orange); border-radius: 0 6px 6px 0; padding: 14px 18px; margin: 16px 0 24px; font-size: 14px; }\n.note-box strong { color: var(--orange); }\n.insight-box { background: var(--teal-pale); border-left: 4px solid var(--teal); border-radius: 0 6px 6px 0; padding: 14px 18px; margin: 16px 0 24px; font-size: 14px; }\n.insight-box strong { color: var(--teal-dark); }\n\n\/* Param cards *\/\n.param-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(180px, 1fr)); gap: 14px; margin: 16px 0 28px; }\n.param-card { background: var(--white); border: 1px solid var(--border); border-top: 3px solid var(--teal); border-radius: 8px; padding: 14px 16px; }\n.param-card .param-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--muted); margin-bottom: 4px; }\n.param-card .param-value { font-size: 18px; font-weight: 700; color: var(--dark); }\n.param-card .param-note { font-size: 12px; color: var(--muted); margin-top: 3px; }\n\n\/* FAQ *\/\n.faq-item { border-bottom: 1px solid var(--border); padding: 18px 0; }\n.faq-item:last-child { border: none; }\n.faq-q { font-weight: 700; color: var(--dark); margin-bottom: 8px; font-size: 16px; }\n.faq-a { font-size: 15px; color: var(--text); margin: 0; }\n\n\/* Related + CTA *\/\n.related-box { background: var(--grey); border-radius: 12px; padding: 28px 32px; margin: 48px 0 24px; }\n.related-title { font-size: 16px; font-weight: 700; color: var(--dark); margin: 0 0 20px; }\n.related-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }\n.related-link { display: block; border: 1px solid var(--border); border-radius: 8px; padding: 14px 18px; background: var(--white); font-size: 14px; font-weight: 500; color: var(--dark); text-decoration: none; }\n.related-link:hover { border-color: var(--teal); color: var(--teal-dark); text-decoration: none; }\n.back-link-wrap { text-align: center; margin: 24px 0 40px; }\n.back-link { color: var(--teal-dark); font-weight: 600; font-size: 15px; }\n.cta-box { background: var(--grey); border-radius: 12px; padding: 48px 40px; text-align: center; margin-bottom: 48px; }\n.cta-title { font-size: 24px; font-weight: 700; color: var(--dark); margin: 0 0 14px; }\n.cta-text { font-size: 15px; color: var(--text); max-width: 600px; margin: 0 auto 12px; }\n.cta-contact { font-size: 14px; color: var(--muted); margin-bottom: 28px; }\n.cta-contact a { color: var(--teal-dark); }\n.cta-buttons { display: flex; justify-content: center; gap: 16px; flex-wrap: wrap; }\n.cta-btn-primary { background: var(--teal); color: var(--white); padding: 14px 32px; border-radius: 50px; font-size: 13px; font-weight: 700; letter-spacing: 0.5px; text-decoration: none; }\n.cta-btn-primary:hover { background: var(--teal-dark); text-decoration: none; }\n.cta-btn-outline { border: 2px solid var(--teal); color: var(--teal-dark); padding: 14px 32px; border-radius: 50px; font-size: 13px; font-weight: 700; text-decoration: none; }\n.cta-btn-outline:hover { background: var(--teal-pale); text-decoration: none; }\n\n@media (max-width: 640px) {\n .hero { grid-template-columns: 1fr; padding: 32px 24px; }\n .hero-right { flex-direction: row; }\n .hero-stat { flex: 1; }\n h1 { font-size: 22px; }\n h2 { font-size: 18px; }\n .decision-grid, .alt-grid { grid-template-columns: 1fr; }\n .related-grid { grid-template-columns: 1fr; }\n .cta-box { padding: 32px 20px; }\n .spec-table { font-size: 13px; }\n .spec-table th, .spec-table td { padding: 8px 10px; }\n}\n<\/style>\n<\/head>\n<body>\n\n\n<div class=\"hero\">\n <div class=\"hero-left\">\n <div class=\"eyebrow\">Protocol Guide \u00b7 Serum Strategy<\/div>\n <h1>Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives<\/h1>\n <p class=\"lead\">When to go stepwise, when to switch directly, and which alternative \u2014 hPL, human serum, rHSA, recombinant transferrin \u2014 actually works for your cell type and application.<\/p>\n <div class=\"hero-tags\">\n <span class=\"tag\">Stepwise Adaptation<\/span>\n <span class=\"tag\">hPL<\/span>\n <span class=\"tag\">Menschliches Serum<\/span>\n <span class=\"tag\">rHSA<\/span>\n <span class=\"tag\">Xeno-frei<\/span>\n <span class=\"tag\">GMP-kompatibel<\/span>\n <\/div>\n <\/div>\n <div class=\"hero-right\">\n <div class=\"hero-stat\"><div class=\"stat-num\">5<\/div><div class=\"stat-label\">FBS alternatives compared<\/div><\/div>\n <div class=\"hero-stat\"><div class=\"stat-num\">8<\/div><div class=\"stat-label\">Antworten auf h\u00e4ufig gestellte Fragen<\/div><\/div>\n <\/div>\n<\/div>\n\n\n<div class=\"quick-answer\">\n <div class=\"qa-label\">Kurze Antwort<\/div>\n <p><strong>Is serum actually bad for cell culture?<\/strong> No \u2014 serum is not inherently problematic. It is a rich, biologically complex supplement that provides growth factors, carrier proteins, lipids and trace elements that many cells genuinely need. The problems with FBS specifically are lot-to-lot variability, animal origin (relevant for GMP and xeno-free applications), and undefined composition that makes results difficult to reproduce across labs. The goal of serum-free or human-derived serum strategies is not to remove all serum-like function, but to replace it with something more consistent, defined, or ethically aligned \u2014 while retaining equivalent biological performance.<\/p>\n<\/div>\n\n\n<div class=\"toc\">\n <h4>Inhaltsverzeichnis<\/h4>\n <ol>\n <li><a href=\"#why\">Why go serum-free? The real reasons<\/a><\/li>\n <li><a href=\"#decision\">Direct switch vs. stepwise adaptation \u2014 how to decide<\/a><\/li>\n <li><a href=\"#protocol\">Stepwise adaptation protocol \u2014 step by step<\/a><\/li>\n <li><a href=\"#alternatives\">FBS alternatives: hPL, human serum, rHSA, recombinant components<\/a><\/li>\n <li><a href=\"#comparison\">Full comparison: FBS vs. all alternatives<\/a><\/li>\n <li><a href=\"#celltype\">Cell-type specific recommendations<\/a><\/li>\n <li><a href=\"#troubleshooting\">Troubleshooting failed adaptations<\/a><\/li>\n <li><a href=\"#faq\">H\u00e4ufig gestellte Fragen<\/a><\/li>\n <\/ol>\n<\/div>\n\n\n<h2 id=\"why\">1. Why Go Serum-Free? The Real Reasons<\/h2>\n\n<p>The motivation matters enormously because it determines which alternative is correct. There is no single \"best\" serum-free approach \u2014 the right path depends entirely on why you are leaving FBS.<\/p>\n\n<table class=\"spec-table\">\n <tr><th>Reason for leaving FBS<\/th><th>The actual problem<\/th><th>Best solution<\/th><\/tr>\n <tr><td><strong>Chargen-zu-Chargen-Schwankungen<\/strong><\/td><td>Growth factor composition varies between lots; IC50 shifts, differentiation efficiency changes<\/td><td>Batch reservation of FBS, or switch to hPL (pooled donors, more consistent)<\/td><\/tr>\n <tr><td><strong>Regulatory \/ GMP requirements<\/strong><\/td><td>Animal-derived raw materials require TSE\/BSE risk assessment; regulators prefer defined media<\/td><td>hPL (human-derived, GMP-grade available), rHSA + defined growth factors<\/td><\/tr>\n <tr><td><strong>Xeno-free for human cell therapy<\/strong><\/td><td>Bovine proteins can trigger immunogenic reactions in patients; not acceptable for ATMP manufacturing<\/td><td>hPL, human AB serum, rHSA, recombinant human growth factors<\/td><\/tr>\n <tr><td><strong>Defined composition for mechanistic research<\/strong><\/td><td>Unknown serum components confound interpretation of signalling experiments<\/td><td>Chemically defined serum-free medium + specific recombinant growth factors<\/td><\/tr>\n <tr><td><strong>Cost at large scale<\/strong><\/td><td>10% FBS in a 200 L bioreactor is economically unviable<\/td><td>Serum-free suspension medium (CDM) + rHSA carrier<\/td><\/tr>\n <tr><td><strong>Ethical \/ 3R compliance<\/strong><\/td><td>FBS is collected from foetal bovine blood during slaughter<\/td><td>hPL, human serum (donor-consented), plant-derived or recombinant components<\/td><\/tr>\n<\/table>\n\n<div class=\"insight-box\">\n <strong>Key insight:<\/strong> Serum itself \u2014 as a concept \u2014 is not the problem. The biologically complex, growth-factor-rich environment serum provides is often exactly what cells need. Human platelet lysate (hPL) and human serum are not \"serum-free\" in the biological sense \u2014 they are serum-equivalent supplements from a human source. True serum-free means chemically defined medium with recombinant growth factors. Choose based on your actual goal, not on a blanket assumption that \"serum-free = better.\"\n<\/div>\n\n\n<h2 id=\"decision\">2. Direct Switch vs. Stepwise Adaptation \u2014 How to Decide<\/h2>\n\n<p>Not all cells need a stepwise transition. Forcing a slow adaptation on a cell line that would tolerate a direct switch wastes 3\u20134 weeks unnecessarily. Equally, switching a primary cell directly to serum-free without adaptation will often cause apoptosis within 48 hours. The decision tree is straightforward:<\/p>\n\n<div class=\"decision-grid\">\n <div class=\"decision-card go\">\n <div class=\"dc-label\">\u2713 Direct switch \u2014 safe<\/div>\n <h3>Switch immediately<\/h3>\n <ul>\n <li>Established cancer cell lines (HeLa, A549, MCF-7, HEK293T, CHO)<\/li>\n <li>Already adapted suspension lines<\/li>\n <li>Switching FBS \u2192 hPL (same concentration)<\/li>\n <li>Switching FBS \u2192 human serum (same concentration)<\/li>\n <li>Lines already tested successfully by others in the same medium<\/li>\n <\/ul>\n <\/div>\n <div class=\"decision-card slow\">\n <div class=\"dc-label\">\u26a0 Stepwise \u2014 recommended<\/div>\n <h3>Adapt gradually<\/h3>\n <ul>\n <li>Primary cells (fibroblasts, endothelial, epithelial)<\/li>\n <li>Hybridomas switching to serum-free<\/li>\n <li>MSCs, stromal cells<\/li>\n <li>Any FBS \u2192 chemically defined switch<\/li>\n <li>Adherent lines switching to suspension<\/li>\n <li>Sensitive or slow-growing lines<\/li>\n <\/ul>\n <\/div>\n <div class=\"decision-card no\">\n <div class=\"dc-label\">\u2717 May not adapt<\/div>\n <h3>High failure risk<\/h3>\n <ul>\n <li>Neurons and post-mitotic cells<\/li>\n <li>~3\u20135% of hybridoma lines<\/li>\n <li>Highly serum-dependent primary cells<\/li>\n <li>iPSC lines outside defined maintenance media<\/li>\n <li>Cells with no published serum-free protocol<\/li>\n <\/ul>\n <\/div>\n<\/div>\n\n<div class=\"note-box\">\n <strong>Rule of thumb:<\/strong> If you are switching FBS for another human-derived serum-equivalent (hPL or human AB serum) at the same concentration \u2014 try direct first. If you are switching to chemically defined serum-free medium \u2014 always go stepwise. If your cell line has never been cultured serum-free in any published protocol \u2014 verify feasibility before committing.\n<\/div>\n\n\n<h2 id=\"protocol\">3. Stepwise Adaptation Protocol \u2014 Step by Step<\/h2>\n\n<p>The stepwise protocol below applies to: any adherent cell line transitioning to chemically defined serum-free medium, hybridomas, MSCs, and primary cells. For FBS \u2192 hPL transitions, compress the timeline to 2\u20134 passages at matching concentration before reducing.<\/p>\n\n<div class=\"steps\">\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Baseline characterisation (before you start)<\/h3>\n <p>Document your cell line's current doubling time, morphology, viability at passage, and any assay-specific performance metrics (IC50, transfection efficiency, marker expression). This is your reference \u2014 you cannot evaluate adaptation success without it. Freeze down at least 3 vials of early-passage cells before starting. If adaptation fails, you need to restart from here.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 1\u20132: 75% FBS \/ 25% target medium<\/h3>\n <p>Replace 25% of your standard FBS medium volume with the target serum-free or alternative medium. Cells are exposed to the new environment gradually while retaining 75% of their normal support. Monitor viability and doubling time. If viability drops below 80% within 48 h \u2014 slow down. If cells maintain >90% viability and normal morphology \u2014 proceed.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 3\u20134: 50% \/ 50%<\/h3>\n <p>Equal mix of standard and target medium. This is often the most critical step \u2014 cells that will fail adaptation frequently show signs here: rounding, detachment, reduced proliferation. Allow 2 full passages at this ratio. If doubling time increases by more than 50% compared to baseline \u2014 pause and assess before proceeding. Consider adding ROCK inhibitor (Y-27632, 10 \u00b5M) for sensitive adherent cells during this step to reduce anoikis.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 5\u20136: 25% FBS \/ 75% target medium<\/h3>\n <p>Final approach. At this stage, most cells that will adapt have already made the metabolic adjustment. The remaining FBS provides a residual survival signal that is now withdrawn almost completely. Monitor closely: if viability is stable at >85% and morphology is normal \u2014 you are close. If not \u2014 hold at this ratio for 1\u20132 additional passages before proceeding.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 7+: 100% target medium<\/h3>\n <p>Full transition. Allow 3\u20135 passages to stabilise before using cells for experiments. Re-measure your baseline metrics: doubling time, viability, assay performance. If all metrics are within 20% of the FBS baseline \u2014 adaptation is successful. Freeze down adapted cells in new cryoprotective medium appropriate for the target medium (hPL-based or serum-free freezing medium).<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Validation<\/h3>\n <p>Run your key assay (cytotoxicity, transfection, differentiation, migration) in adapted vs. original FBS conditions. Document: doubling time, viability at passage, morphology, and assay-specific endpoint. This validation is required before switching any production workflow \u2014 and is the data package that justifies the transition to QA\/regulatory stakeholders.<\/p>\n <\/div>\n <\/div>\n\n<\/div>\n\n\n<div style=\"background:linear-gradient(135deg,#1a2e35 0%,#2e4a54 100%);border-radius:12px;padding:32px 36px;margin:32px 0;\">\n <div style=\"font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:#18b7b2;margin-bottom:10px;\">Critical Tool for Adaptation Monitoring<\/div>\n <h3 style=\"color:#ffffff;font-size:20px;margin:0 0 12px;\">zenCELL owl \u2014 Continuous Incubator Monitoring During Adaptation<\/h3>\n <p style=\"color:rgba(255,255,255,0.88);font-size:15px;margin-bottom:10px;\">Serum-free adaptation fails quietly. Confluence drops by 5% overnight. Cells round slightly over a weekend. Doubling time increases by 2 hours \u2014 and by Monday, you have lost the passage. The zenCELL owl live cell imager sits inside your CO\u2082 incubator and captures brightfield images of all 24 wells continuously, at intervals as short as 1 minute.<\/p>\n <p style=\"color:rgba(255,255,255,0.88);font-size:15px;margin-bottom:16px;\">During each adaptation step, the owl tracks confluence in real time and generates an alert when confluence falls below your defined threshold \u2014 whether you are in the lab, at home, or over a bank holiday. You see exactly when and how fast your cells respond to each medium change. No guesswork. No lost weeks.<\/p>\n <div style=\"display:flex;flex-wrap:wrap;gap:10px;margin-bottom:24px;\">\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Confluence alerts<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">24 Wells gleichzeitig<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Label-free brightfield<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Kinetic time-lapse per passage<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Weekend & night monitoring<\/span>\n <\/div>\n <a href=\"https:\/\/www.zencellowl.com\" target=\"_blank\" rel=\"noopener\" style=\"background:#18b7b2;color:#ffffff;padding:12px 28px;border-radius:50px;font-size:13px;font-weight:700;letter-spacing:0.5px;text-decoration:none;\">Erfahren Sie mehr \u00fcber zenCELL owl \u2192<\/a>\n<\/div>\n\n<div class=\"param-grid\">\n <div class=\"param-card\"><div class=\"param-label\">Typical timeline<\/div><div class=\"param-value\">3\u20136 weeks<\/div><div class=\"param-note\">7+ passages at 3\u20134 day intervals<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Step size<\/div><div class=\"param-value\">25%<\/div><div class=\"param-note\">Per passage; slower for primary cells<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Viability threshold<\/div><div class=\"param-value\">>85%<\/div><div class=\"param-note\">Minimum to proceed to next step<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Freeze backup<\/div><div class=\"param-value\">Before start<\/div><div class=\"param-note\">Minimum 3 vials pre-adaptation<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Stabilisation<\/div><div class=\"param-value\">3\u20135 passages<\/div><div class=\"param-note\">After full switch before experiments<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Failure rate<\/div><div class=\"param-value\">3\u20135%<\/div><div class=\"param-note\">Of all cell lines; higher for primary<\/div><\/div>\n<\/div>\n\n\n<h2 id=\"alternatives\">4. FBS Alternatives \u2014 hPL, Human Serum, rHSA & Recombinant Components<\/h2>\n\n<p>The best alternative depends on your cell type and goal. Below are all options SeamlessBio supplies, with honest assessments of where each works well and where it does not.<\/p>\n\n<div class=\"alt-grid\">\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: MSC, primary human cells, ATMP<\/div>\n <h3>Lysat aus menschlichen Blutpl\u00e4ttchen (hPL)<\/h3>\n <p>Produced by freeze-thaw lysis of human platelets, releasing a concentrated cocktail of growth factors (PDGF, TGF-\u03b2, bFGF, VEGF, EGF, IGF-1) into plasma. Biologically richer than FBS for most human cell types \u2014 especially MSCs, where hPL at 5% outperforms FBS at 10% for proliferation rate. Xeno-free, human-derived, GMP-grade formulations available.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310% in standard basal medium<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\">View Human Serum & hPL portfolio \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Immunoassays, hybridoma, human-specific protocols<\/div>\n <h3>Human AB Serum<\/h3>\n <p>Whole human serum from AB blood group donors \u2014 the universal serum type that avoids ABO antibody interference. Provides species-matched growth factors for human cell lines, eliminates bovine protein contamination, and is directly substitutable for FBS in many protocols at the same concentration. Essential for hybridoma mAb production where bovine IgG co-purification must be avoided, and for any assay involving human immune cells.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310% (same as FBS); direct switch for many human lines<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\">View Human AB Serum \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Serum-free formulation, carrier function, AAV\/bioreactor<\/div>\n <h3>rHSA \u2014 Recombinant Human Serum Albumin<\/h3>\n <p>Albumin accounts for ~60% of total serum protein and provides the carrier function critical for fatty acid delivery, drug solubilisation, and reactive oxygen species scavenging. rHSA (rice-expressed, \u226595% purity) replaces this function in serum-free media without introducing undefined growth factors or animal-derived components. Used in serum-free viral vector production, bioreactor culture, and as a stabiliser in cryopreservation media.<\/p>\n <span class=\"alt-conc\">Typical: 1\u20135 g\/L in serum-free medium<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/albuminproteine\/\">View rHSA \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Iron delivery in serum-free medium<\/div>\n <h3>Recombinant Human Transferrin (OsrhTF)<\/h3>\n <p>Transferrin is the primary iron carrier in serum \u2014 essential for haem synthesis, electron transport and cell proliferation. In serum-free medium, cells become iron-limited within 48\u201372 h without a transferrin source. OsrhTF (rice-expressed, \u226599% purity) provides this function in a defined, animal-free format. Critical component in serum-free media for AAV production, iPSC culture and cultured meat applications.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310 \u00b5g\/mL in serum-free medium<\/span><br>\n <a href=\"https:\/\/shop.seamlessbio.de\/products\/recombinant-human-transferrin-osrhtf\">View OsrhTF \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Blocking, drug solubilisation, assay buffers<\/div>\n <h3>BSA \u2013 Rinderserumalbumin<\/h3>\n <p>BSA is the most widely used serum protein replacement for applications where only the carrier function is needed \u2014 not the full growth factor complex. Used in ELISA blocking, antibody dilution buffers, drug solubilisation, and as a low-cost albumin source in serum-free cell culture medium. Fatty acid-free grade available for receptor and lipid studies.<\/p>\n <span class=\"alt-conc\">Typical: 1\u20136 mg\/mL in serum-free medium or assay buffer<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/bsa\/\">BSA anzeigen \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Chemically defined, mechanistic studies<\/div>\n <h3>Recombinant Growth Factor Cocktails<\/h3>\n <p>For fully defined serum-free conditions, FBS function must be replaced component by component: rIGF-1 (50\u2013100 ng\/mL), rEGF (10\u201320 ng\/mL), rFGF-2 (10 ng\/mL), rInsulin (10 \u00b5g\/mL), rTransferrin (5\u201310 \u00b5g\/mL), Selenium (5 ng\/mL), and rHSA (1\u20132 g\/L) as carrier. This approach gives maximum control over the signalling environment but requires optimisation per cell type and is expensive at scale.<\/p>\n <span class=\"alt-conc\">Cell-type specific; optimise per application<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">Contact us for component sourcing \u2192<\/a>\n <\/div>\n\n<\/div>\n\n\n<h2 id=\"comparison\">5. Full Comparison: FBS vs. All Alternatives<\/h2>\n\n<table class=\"spec-table\">\n <tr>\n <th>Supplement<\/th>\n <th>Herkunft<\/th>\n <th>Defined?<\/th>\n <th>Xeno-free?<\/th>\n <th>GMP-grade?<\/th>\n <th>Lot consistency<\/th>\n <th>Am besten geeignet f\u00fcr<\/th>\n <\/tr>\n <tr>\n <td><strong>FBS-Standard<\/strong><\/td>\n <td>Bovine foetal<\/td>\n <td>Nein<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Medium (lot-tested)<\/td>\n <td>General research, most cell lines<\/td>\n <\/tr>\n <tr>\n <td><strong>FBS, endotoxinarme<\/strong><\/td>\n <td>Bovine foetal<\/td>\n <td>Nein<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Mittel<\/td>\n <td>Cytokine assays, AAV, drug screening<\/td>\n <\/tr>\n <tr>\n <td><strong>Human AB Serum<\/strong><\/td>\n <td>Human donor<\/td>\n <td>Nein<\/td>\n <td>Ja<\/td>\n <td>Teilweise<\/td>\n <td>Medium (pooled)<\/td>\n <td>Human cell lines, hybridoma, immune assays<\/td>\n <\/tr>\n <tr>\n <td><strong>hPL (Human Platelet Lysate)<\/strong><\/td>\n <td>Human platelets<\/td>\n <td>Nein<\/td>\n <td>Ja<\/td>\n <td>Yes (GMP-grade available)<\/td>\n <td>High (pooled, standardised)<\/td>\n <td>MSC, primary human cells, ATMP manufacturing<\/td>\n <\/tr>\n <tr>\n <td><strong>rHSA<\/strong><\/td>\n <td>Recombinant (rice)<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Serum-free carrier function, bioreactor, AAV<\/td>\n <\/tr>\n <tr>\n <td><strong>OsrhTF (Recombinant Transferrin)<\/strong><\/td>\n <td>Recombinant (rice)<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Iron delivery in serum-free medium<\/td>\n <\/tr>\n <tr>\n <td><strong>BSA Fatty Acid Free<\/strong><\/td>\n <td>Rinder<\/td>\n <td>Teilweise<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Hoch<\/td>\n <td>IVF, assay buffers, blocking<\/td>\n <\/tr>\n <tr>\n <td><strong>Defined growth factor cocktail<\/strong><\/td>\n <td>Recombinant<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Mechanistic research, iPSC, defined protocols<\/td>\n <\/tr>\n<\/table>\n\n\n<h2 id=\"celltype\">6. Cell-Type Specific Recommendations<\/h2>\n\n<table class=\"spec-table\">\n <tr><th>Zelltyp<\/th><th>Recommended Alternative<\/th><th>Direct or Stepwise?<\/th><th>Anmerkungen<\/th><\/tr>\n <tr><td>MSC (bone marrow, adipose)<\/td><td>hPL 5%<\/td><td>Direct or 2-step<\/td><td>hPL outperforms FBS for MSC proliferation; CFU-F rate often higher<\/td><\/tr>\n <tr><td>HEK293 \/ HEK293T<\/td><td>Chemically defined CDM or serum-free SFM<\/td><td>Stepwise (4\u20136 passages)<\/td><td>Suspension adaptation required; HEK293 adapts well, HEK293T less predictably<\/td><\/tr>\n <tr><td>CHO<\/td><td>Chemically defined CDM (CD CHO, BalanCD)<\/td><td>Stepwise<\/td><td>Industry standard; most CHO lines have published serum-free protocols<\/td><\/tr>\n <tr><td>Primary human fibroblasts<\/td><td>hPL 5\u201310%<\/td><td>Direct or 2-step<\/td><td>Human-derived growth factors superior for human primary cells<\/td><\/tr>\n <tr><td>HUVEC \/ endothelial<\/td><td>Human AB Serum 5\u201310% or hPL 5%<\/td><td>Direct<\/td><td>EGM-2 serum-free media also available commercially<\/td><\/tr>\n <tr><td>Hybridom<\/td><td>Serum-free hybridoma SFM, stepwise<\/td><td>Stepwise (8 passages)<\/td><td>3\u20135% failure rate; hPL not recommended for hybridoma (IgG contamination)<\/td><\/tr>\n <tr><td>iPSC \/ hPSC<\/td><td>mTeSR1 \/ TeSR-E8 \/ HiDef-B8 (serum-free)<\/td><td>Direct (switch medium)<\/td><td>Already serum-free in maintenance; FBS only in reprogramming and some differentiation<\/td><\/tr>\n <tr><td>Vero \/ BHK \/ MDCK<\/td><td>VP-SFM, Optipro SFM or CDM<\/td><td>Stepwise<\/td><td>Used in vaccine production; regulatory preference for serum-free<\/td><\/tr>\n <tr><td>Muscle satellite cells (cultured meat)<\/td><td>rHSA + rIGF-1 + rFGF-2 + OsrhTF<\/td><td>Stepwise<\/td><td>Most challenging; still active research area<\/td><\/tr>\n <tr><td>Cancer cell lines (HeLa, A549, MCF-7)<\/td><td>Human AB Serum or hPL at same %<\/td><td>Direct<\/td><td>Most tolerate direct switch; validate assay performance<\/td><\/tr>\n<\/table>\n\n\n<h2 id=\"troubleshooting\">7. Troubleshooting Failed Adaptations<\/h2>\n\n<table class=\"spec-table\">\n <tr><th>Problem<\/th><th>Most likely cause<\/th><th>L\u00f6sung<\/th><\/tr>\n <tr><td>Cells detach and die within 48 h of switch<\/td><td>Missing attachment factors (fibronectin, vitronectin) normally supplied by FBS<\/td><td>Pre-coat flasks with fibronectin (10 \u00b5g\/mL) or vitronectin; add rHSA as attachment carrier<\/td><\/tr>\n <tr><td>Cells survive but stop proliferating<\/td><td>Missing growth factors \u2014 IGF-1, EGF or FGF typically rate-limiting<\/td><td>Add rIGF-1 (50 ng\/mL) and rEGF (20 ng\/mL) to serum-free medium; optimise stepwise<\/td><\/tr>\n <tr><td>Progressive viability loss over passages<\/td><td>Iron deficiency \u2014 transferrin function not replaced<\/td><td>Add recombinant transferrin (OsrhTF, 5\u201310 \u00b5g\/mL) or iron-saturated transferrin<\/td><\/tr>\n <tr><td>Cells aggregate in suspension<\/td><td>Absence of anti-clumping agents or shear stress from agitation<\/td><td>Add anti-clumping agent (0.1% methylcellulose or proprietary); optimise agitation speed<\/td><\/tr>\n <tr><td>Phenotypic drift after adaptation<\/td><td>Growth factor pressure selects for a subpopulation; or stress-induced epigenetic changes<\/td><td>Re-thaw from pre-adaptation stock; validate markers; consider less aggressive adaptation<\/td><\/tr>\n <tr><td>Adaptation successful but assay performance changes<\/td><td>Serum components were part of the assay readout (e.g. albumin binding, complement activity)<\/td><td>Recalibrate assay controls; run side-by-side comparison; adjust compound concentrations<\/td><\/tr>\n <tr><td>hPL causes clot\/gel formation in flask<\/td><td>Residual fibrinogen in hPL activating clotting cascade<\/td><td>Switch to heparin-free (fibrinogen-depleted) hPL formulation; add heparin (2 U\/mL) if using standard hPL<\/td><\/tr>\n<\/table>\n\n\n<h2 id=\"faq\">8. H\u00e4ufig gestellte Fragen<\/h2>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Is serum-free always better than serum-containing medium?<\/div>\n <p class=\"faq-a\">No \u2014 this is one of the most common misconceptions in cell biology. Serum provides a complex, biologically relevant environment that many cells \u2014 especially primary cells \u2014 genuinely require. Serum-free media can reduce variability and improve regulatory compliance, but they often require optimisation per cell type and can alter phenotype or assay sensitivity. The correct question is not \"serum vs. serum-free\" but \"which supplement gives the most consistent, biologically appropriate, and application-suitable result for my specific cell type and goal?\"<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Can I switch FBS directly for human serum or hPL?<\/div>\n <p class=\"faq-a\">For most established human cell lines \u2014 yes. Human AB serum and hPL are biologically equivalent to FBS in terms of growth support, and for human cells they are often superior. Start with a direct switch at the same concentration (10% hPL or human AB serum replacing 10% FBS). If viability and doubling time are maintained after 2\u20133 passages, adaptation is successful. A stepwise transition is rarely necessary for this specific switch.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">What is human platelet lysate (hPL) and how does it compare to FBS?<\/div>\n <p class=\"faq-a\">hPL is produced by freeze-thaw lysis of human platelets, releasing a concentrated pool of growth factors including PDGF, TGF-\u03b2, bFGF, VEGF, EGF and IGF-1. For human cell types \u2014 particularly MSCs, fibroblasts and other primary human cells \u2014 hPL at 5% is frequently superior to FBS at 10% in terms of proliferation rate and maintenance of phenotypic characteristics. It is xeno-free, human-derived, and GMP-grade formulations are available for ATMP manufacturing. Its main limitations are: requires heparin addition to prevent clotting (or use heparin-free\/fibrinogen-depleted hPL), lot-to-lot variability remains (though lower than FBS with large pooling), and it is not suitable for hybridoma culture (introduces human IgG that co-purifies with murine mAb).<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">What does recombinant human transferrin (OsrhTF) do in serum-free medium?<\/div>\n <p class=\"faq-a\">Transferrin is the primary iron delivery protein in serum. It binds iron in circulation and delivers it to cells via transferrin receptor-mediated endocytosis \u2014 triggering receptor recycling and intracellular iron release. Without a transferrin source in serum-free medium, cells become iron-limited within 48\u201372 hours and show reduced proliferation, mitochondrial dysfunction, and eventual apoptosis. OsrhTF (rice-expressed, \u226599% purity) is used at 5\u201310 \u00b5g\/mL in serum-free medium to replace this function. It is animal-free, defined, and fully recombinant \u2014 compatible with GMP and ATMP applications.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">How long does serum-free adaptation take?<\/div>\n <p class=\"faq-a\">For established cancer cell lines switching from FBS to human serum or hPL: often 1\u20133 passages (1\u20132 weeks). For stepwise transition to chemically defined serum-free medium: typically 7\u201310 passages (3\u20136 weeks) using 25% incremental reduction per 2 passages. For suspension adaptation of adherent lines (e.g. HEK293 for bioreactor production): 4\u20138 weeks including suspension adaptation and performance validation. Always allow 3\u20135 additional passages after the final switch before using cells for experiments, to ensure phenotypic stability.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Should I add ROCK inhibitor during serum-free adaptation?<\/div>\n <p class=\"faq-a\">Yes \u2014 for sensitive adherent cell types (primary cells, iPSC-derived cells, some hybridomas during adaptation), adding Y-27632 (ROCK inhibitor, 10 \u00b5M) during the 48\u201372 h immediately after each medium change significantly reduces anoikis (detachment-induced apoptosis). This is particularly useful at the 50% and 75% serum-free stages where anoikis risk is highest. Remove Y-27632 after the adaptation period \u2014 do not use it permanently as it can alter cytoskeletal organisation and migration phenotype.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Can rHSA replace BSA in cell culture medium?<\/div>\n <p class=\"faq-a\">Yes \u2014 rHSA (recombinant human serum albumin) can replace BSA in most serum-free cell culture applications where albumin is used as a carrier, stabiliser or fatty acid source. rHSA is human-sequence albumin expressed in rice, is animal-free, and has higher lot-to-lot consistency than BSA (which is bovine-derived). For GMP and xeno-free applications, rHSA is the preferred choice. For cost-sensitive non-GMP research applications, BSA remains widely used due to price advantage.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Which cells cannot be adapted to serum-free conditions?<\/div>\n <p class=\"faq-a\">Post-mitotic neurons and terminally differentiated cells typically cannot be maintained serum-free without highly specialised neuronal media (e.g. Neurobasal + B27). Approximately 3\u20135% of hybridoma lines fail serum-free adaptation regardless of protocol \u2014 use FBS Ultra Low IgG as the alternative in these cases. Highly serum-dependent primary cells (some hepatocyte preparations, some smooth muscle cells) may require serum at low concentrations (<2%) permanently. If a cell type has no published serum-free protocol in PubMed, expect significant optimisation time before achieving equivalent performance.<\/p>\n<\/div>\n\n\n<div class=\"related-box\">\n <h3 class=\"related-title\">Verwandte Anwendungen und Produkte<\/h3>\n <div class=\"related-grid\">\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\" class=\"related-link\">\u2192 Human AB Serum \u2014 Mixed Donors & Type AB<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/albuminproteine\/\" class=\"related-link\">\u2192 rHSA \u2014 Recombinant Human Serum Albumin<\/a>\n <a href=\"https:\/\/shop.seamlessbio.de\/products\/recombinant-human-transferrin-osrhtf\" class=\"related-link\">\u2192 OsrhTF \u2014 Recombinant Human Transferrin<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/bsa\/\" class=\"related-link\">\u2192 BSA \u2014 Standard, Low Endotoxin, Fatty Acid Free<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/ipsc-stem-cell-culture\/\" class=\"related-link\">\u2192 iPSC & Stem Cell Culture \u2014 Medium Guide<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/aav-viral-vector-production\/\" class=\"related-link\">\u2192 AAV Viral Vector Production \u2014 Serum Strategy<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/hybridoma-monoclonal-antibody-production\/\" class=\"related-link\">\u2192 Hybridoma & mAb Production \u2014 Low IgG FBS Guide<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/fotales-rinderserum\/\" class=\"related-link\">\u2192 FBS Portfolio \u2014 All Grades<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/uberwachung-lebender-zellen\/\" class=\"related-link\">\u2192 Live Cell Monitoring \u2014 zenCELL owl Guide<\/a>\n <a href=\"https:\/\/www.zencellowl.com\" class=\"related-link\">\u2192 zenCELL-Eule-Website<\/a>\n <\/div>\n<\/div>\n\n<div class=\"back-link-wrap\">\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/\" class=\"back-link\">\u2190 \u00dcbersicht \u00fcber alle Anwendungsleitf\u00e4den<\/a>\n<\/div>\n\n\n<div class=\"cta-box\">\n <h2 class=\"cta-title\">Sample Set for Serum-Free Transition<\/h2>\n <p class=\"cta-text\">Request test volumes of Human AB Serum, rHSA and OsrhTF alongside your current FBS lot \u2014 run your own side-by-side comparison before committing to a transition.<\/p>\n <p class=\"cta-contact\">E-Mail: info@seamlessbio.de | +49 851 37932226 | <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">seamlessbio.de\/kontakt<\/a><\/p>\n <div class=\"cta-buttons\">\n <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"cta-btn-primary\">REQUEST SAMPLE SET<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\" class=\"cta-btn-outline\">HUMAN SERUM PORTFOLIO \u2192<\/a>\n <\/div>\n<\/div>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives | SeamlessBio Protocol Guide \u00b7 Serum Strategy Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives When to go stepwise, when […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-2736","page","type-page","status-publish","hentry"],"yoast_head":"\n<title>Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio<\/title>\n<meta name=\"description\" content=\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serum-Free Cell Culture Guide\" \/>\n<meta property=\"og:description\" content=\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T12:14:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"14\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\",\"name\":\"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-07-17T12:14:26+00:00\",\"dateModified\":\"2026-07-17T12:14:28+00:00\",\"description\":\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serum-Free Cell Culture Guide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\"},\"telephone\":[],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\",\"Sunday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"}]}<\/script>\n","yoast_head_json":{"title":"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio","description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/","og_locale":"de_DE","og_type":"article","og_title":"Serum-Free Cell Culture Guide","og_description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","og_url":"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/","og_site_name":"SeamlessBio","article_modified_time":"2026-07-17T12:14:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"14\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/","url":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/","name":"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-07-17T12:14:26+00:00","dateModified":"2026-07-17T12:14:28+00:00","description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Serum-Free Cell Culture Guide"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo"},"telephone":[],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday","Sunday"],"opens":"09:00","closes":"17:00"}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=2736"}],"version-history":[{"count":5,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736\/revisions"}],"predecessor-version":[{"id":2741,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736\/revisions\/2741"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=2736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n \t\t

\n\t\t\t\t\t\n\n\n\n\nSerum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives | SeamlessBio<\/title>\n\n<style>\n:root {\n --teal: #18b7b2; --teal-dark: #139b97; --teal-pale: #e9fbfa;\n --dark: #1a2e35; --mid: #2e4a54; --grey: #f4f6f7;\n --border: #d8e8e7; --text: #2c3e3f; --muted: #6b7f82;\n --white: #ffffff; --orange: #e07b00; --green: #1a7f4b;\n}\n*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\nbody { font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 16px; line-height: 1.7; color: var(--text); background: var(--white); max-width: 1100px; margin: 0 auto; padding: 0 20px; }\nh1 { font-size: 32px; font-weight: 800; color: var(--dark); line-height: 1.2; }\nh2 { font-size: 22px; font-weight: 700; color: var(--dark); margin: 48px 0 16px; padding-bottom: 8px; border-bottom: 2px solid var(--teal); }\nh3 { font-size: 17px; font-weight: 700; color: var(--dark); margin: 24px 0 10px; }\np { margin-bottom: 14px; }\na { color: var(--teal-dark); text-decoration: none; }\na:hover { text-decoration: underline; }\nul, ol { padding-left: 20px; margin-bottom: 14px; }\nli { margin-bottom: 6px; }\nstrong { color: var(--dark); }\n\n\/* Hero *\/\n.hero { background: linear-gradient(135deg, #18b7b2 0%, #62d0cc 60%, #a8e6e4 100%); border-radius: 16px; padding: 48px 40px; margin: 32px 0 40px; display: grid; grid-template-columns: 1fr 200px; gap: 32px; align-items: center; }\n.hero .eyebrow { display: inline-block; font-size: 11px; font-weight: 700; letter-spacing: 1.5px; text-transform: uppercase; color: rgba(255,255,255,0.9); background: rgba(0,0,0,0.15); border-radius: 20px; padding: 4px 14px; margin-bottom: 16px; }\n.hero h1 { color: var(--white); font-size: 28px; text-shadow: 0 1px 3px rgba(0,0,0,0.25); margin-bottom: 12px; }\n.hero .lead { font-size: 16px; color: rgba(255,255,255,0.95); line-height: 1.6; text-shadow: 0 1px 2px rgba(0,0,0,0.2); margin: 0 0 20px; }\n.hero-tags { display: flex; flex-wrap: wrap; gap: 8px; }\n.tag { background: rgba(0,0,0,0.15); border: 1px solid rgba(255,255,255,0.3); color: var(--white); font-size: 12px; font-weight: 600; padding: 4px 12px; border-radius: 20px; }\n.hero-right { display: flex; flex-direction: column; gap: 16px; }\n.hero-stat { background: rgba(0,0,0,0.15); border-radius: 12px; padding: 20px; text-align: center; color: var(--white); }\n.hero-stat .stat-num { font-size: 28px; font-weight: 700; line-height: 1; }\n.hero-stat .stat-label { font-size: 12px; color: rgba(255,255,255,0.85); margin-top: 6px; }\n\n\/* Quick Answer *\/\n.quick-answer { background: var(--teal-pale); border-left: 4px solid var(--teal); border-radius: 0 8px 8px 0; padding: 20px 24px; margin: 0 0 40px; }\n.quick-answer .qa-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--teal-dark); margin-bottom: 8px; }\n.quick-answer p { margin: 0; font-size: 15px; }\n\n\/* TOC *\/\n.toc { background: var(--grey); border-radius: 8px; padding: 20px 24px; margin-bottom: 40px; }\n.toc h4 { font-size: 13px; text-transform: uppercase; letter-spacing: 1px; color: var(--muted); margin-bottom: 12px; }\n.toc ol { margin: 0; padding-left: 18px; }\n.toc li { font-size: 14px; margin-bottom: 4px; }\n\n\/* Decision matrix *\/\n.decision-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 16px; margin: 20px 0 32px; }\n.decision-card { border-radius: 10px; padding: 20px 22px; }\n.decision-card.go { background: #f0fdf4; border: 1px solid #86efac; border-left: 4px solid var(--green); }\n.decision-card.slow { background: #fff8e6; border: 1px solid #fcd34d; border-left: 4px solid var(--orange); }\n.decision-card.no { background: #fef2f2; border: 1px solid #fca5a5; border-left: 4px solid #dc2626; }\n.decision-card .dc-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 8px; }\n.decision-card.go .dc-label { color: var(--green); }\n.decision-card.slow .dc-label { color: var(--orange); }\n.decision-card.no .dc-label { color: #dc2626; }\n.decision-card h3 { font-size: 15px; margin: 0 0 8px; }\n.decision-card ul { font-size: 14px; margin: 0; color: var(--text); }\n\n\/* Steps *\/\n.steps { counter-reset: step; }\n.step { display: flex; gap: 20px; margin-bottom: 16px; padding: 20px 24px; background: var(--grey); border-radius: 8px; align-items: flex-start; }\n.step-num { counter-increment: step; min-width: 36px; height: 36px; background: var(--teal); color: var(--white); border-radius: 50%; display: flex; align-items: center; justify-content: center; font-weight: 700; font-size: 15px; flex-shrink: 0; }\n.step-num::before { content: counter(step); }\n.step-body h3 { margin: 0 0 6px; font-size: 16px; }\n.step-body p { margin: 0; font-size: 15px; }\n\n\/* Alternative cards *\/\n.alt-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(260px, 1fr)); gap: 20px; margin: 20px 0 32px; }\n.alt-card { border: 1px solid var(--border); border-radius: 12px; padding: 22px 24px; background: var(--white); }\n.alt-card .alt-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--teal-dark); margin-bottom: 8px; }\n.alt-card h3 { font-size: 16px; margin: 0 0 10px; }\n.alt-card p { font-size: 14px; color: var(--muted); margin: 0 0 10px; }\n.alt-card .alt-conc { font-size: 13px; font-weight: 700; color: var(--dark); padding: 4px 10px; background: var(--grey); border-radius: 4px; display: inline-block; margin-bottom: 12px; }\n.alt-card a { font-size: 13px; font-weight: 700; color: var(--teal-dark); }\n\n\/* Comparison table *\/\n.spec-table { width: 100%; border-collapse: collapse; margin: 16px 0 24px; font-size: 15px; }\n.spec-table th { background: var(--dark); color: var(--white); padding: 10px 14px; text-align: left; font-size: 13px; font-weight: 600; }\n.spec-table td { padding: 10px 14px; border-bottom: 1px solid var(--border); vertical-align: top; }\n.spec-table tr:nth-child(even) td { background: var(--grey); }\n\n\/* Note \/ pro-serum box *\/\n.note-box { background: #fff8e6; border-left: 4px solid var(--orange); border-radius: 0 6px 6px 0; padding: 14px 18px; margin: 16px 0 24px; font-size: 14px; }\n.note-box strong { color: var(--orange); }\n.insight-box { background: var(--teal-pale); border-left: 4px solid var(--teal); border-radius: 0 6px 6px 0; padding: 14px 18px; margin: 16px 0 24px; font-size: 14px; }\n.insight-box strong { color: var(--teal-dark); }\n\n\/* Param cards *\/\n.param-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(180px, 1fr)); gap: 14px; margin: 16px 0 28px; }\n.param-card { background: var(--white); border: 1px solid var(--border); border-top: 3px solid var(--teal); border-radius: 8px; padding: 14px 16px; }\n.param-card .param-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 1px; color: var(--muted); margin-bottom: 4px; }\n.param-card .param-value { font-size: 18px; font-weight: 700; color: var(--dark); }\n.param-card .param-note { font-size: 12px; color: var(--muted); margin-top: 3px; }\n\n\/* FAQ *\/\n.faq-item { border-bottom: 1px solid var(--border); padding: 18px 0; }\n.faq-item:last-child { border: none; }\n.faq-q { font-weight: 700; color: var(--dark); margin-bottom: 8px; font-size: 16px; }\n.faq-a { font-size: 15px; color: var(--text); margin: 0; }\n\n\/* Related + CTA *\/\n.related-box { background: var(--grey); border-radius: 12px; padding: 28px 32px; margin: 48px 0 24px; }\n.related-title { font-size: 16px; font-weight: 700; color: var(--dark); margin: 0 0 20px; }\n.related-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }\n.related-link { display: block; border: 1px solid var(--border); border-radius: 8px; padding: 14px 18px; background: var(--white); font-size: 14px; font-weight: 500; color: var(--dark); text-decoration: none; }\n.related-link:hover { border-color: var(--teal); color: var(--teal-dark); text-decoration: none; }\n.back-link-wrap { text-align: center; margin: 24px 0 40px; }\n.back-link { color: var(--teal-dark); font-weight: 600; font-size: 15px; }\n.cta-box { background: var(--grey); border-radius: 12px; padding: 48px 40px; text-align: center; margin-bottom: 48px; }\n.cta-title { font-size: 24px; font-weight: 700; color: var(--dark); margin: 0 0 14px; }\n.cta-text { font-size: 15px; color: var(--text); max-width: 600px; margin: 0 auto 12px; }\n.cta-contact { font-size: 14px; color: var(--muted); margin-bottom: 28px; }\n.cta-contact a { color: var(--teal-dark); }\n.cta-buttons { display: flex; justify-content: center; gap: 16px; flex-wrap: wrap; }\n.cta-btn-primary { background: var(--teal); color: var(--white); padding: 14px 32px; border-radius: 50px; font-size: 13px; font-weight: 700; letter-spacing: 0.5px; text-decoration: none; }\n.cta-btn-primary:hover { background: var(--teal-dark); text-decoration: none; }\n.cta-btn-outline { border: 2px solid var(--teal); color: var(--teal-dark); padding: 14px 32px; border-radius: 50px; font-size: 13px; font-weight: 700; text-decoration: none; }\n.cta-btn-outline:hover { background: var(--teal-pale); text-decoration: none; }\n\n@media (max-width: 640px) {\n .hero { grid-template-columns: 1fr; padding: 32px 24px; }\n .hero-right { flex-direction: row; }\n .hero-stat { flex: 1; }\n h1 { font-size: 22px; }\n h2 { font-size: 18px; }\n .decision-grid, .alt-grid { grid-template-columns: 1fr; }\n .related-grid { grid-template-columns: 1fr; }\n .cta-box { padding: 32px 20px; }\n .spec-table { font-size: 13px; }\n .spec-table th, .spec-table td { padding: 8px 10px; }\n}\n<\/style>\n<\/head>\n<body>\n\n\n<div class=\"hero\">\n <div class=\"hero-left\">\n <div class=\"eyebrow\">Protocol Guide \u00b7 Serum Strategy<\/div>\n <h1>Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives<\/h1>\n <p class=\"lead\">When to go stepwise, when to switch directly, and which alternative \u2014 hPL, human serum, rHSA, recombinant transferrin \u2014 actually works for your cell type and application.<\/p>\n <div class=\"hero-tags\">\n <span class=\"tag\">Stepwise Adaptation<\/span>\n <span class=\"tag\">hPL<\/span>\n <span class=\"tag\">Menschliches Serum<\/span>\n <span class=\"tag\">rHSA<\/span>\n <span class=\"tag\">Xeno-frei<\/span>\n <span class=\"tag\">GMP-kompatibel<\/span>\n <\/div>\n <\/div>\n <div class=\"hero-right\">\n <div class=\"hero-stat\"><div class=\"stat-num\">5<\/div><div class=\"stat-label\">FBS alternatives compared<\/div><\/div>\n <div class=\"hero-stat\"><div class=\"stat-num\">8<\/div><div class=\"stat-label\">Antworten auf h\u00e4ufig gestellte Fragen<\/div><\/div>\n <\/div>\n<\/div>\n\n\n<div class=\"quick-answer\">\n <div class=\"qa-label\">Kurze Antwort<\/div>\n <p><strong>Is serum actually bad for cell culture?<\/strong> No \u2014 serum is not inherently problematic. It is a rich, biologically complex supplement that provides growth factors, carrier proteins, lipids and trace elements that many cells genuinely need. The problems with FBS specifically are lot-to-lot variability, animal origin (relevant for GMP and xeno-free applications), and undefined composition that makes results difficult to reproduce across labs. The goal of serum-free or human-derived serum strategies is not to remove all serum-like function, but to replace it with something more consistent, defined, or ethically aligned \u2014 while retaining equivalent biological performance.<\/p>\n<\/div>\n\n\n<div class=\"toc\">\n <h4>Inhaltsverzeichnis<\/h4>\n <ol>\n <li><a href=\"#why\">Why go serum-free? The real reasons<\/a><\/li>\n <li><a href=\"#decision\">Direct switch vs. stepwise adaptation \u2014 how to decide<\/a><\/li>\n <li><a href=\"#protocol\">Stepwise adaptation protocol \u2014 step by step<\/a><\/li>\n <li><a href=\"#alternatives\">FBS alternatives: hPL, human serum, rHSA, recombinant components<\/a><\/li>\n <li><a href=\"#comparison\">Full comparison: FBS vs. all alternatives<\/a><\/li>\n <li><a href=\"#celltype\">Cell-type specific recommendations<\/a><\/li>\n <li><a href=\"#troubleshooting\">Troubleshooting failed adaptations<\/a><\/li>\n <li><a href=\"#faq\">H\u00e4ufig gestellte Fragen<\/a><\/li>\n <\/ol>\n<\/div>\n\n\n<h2 id=\"why\">1. Why Go Serum-Free? The Real Reasons<\/h2>\n\n<p>The motivation matters enormously because it determines which alternative is correct. There is no single \"best\" serum-free approach \u2014 the right path depends entirely on why you are leaving FBS.<\/p>\n\n<table class=\"spec-table\">\n <tr><th>Reason for leaving FBS<\/th><th>The actual problem<\/th><th>Best solution<\/th><\/tr>\n <tr><td><strong>Chargen-zu-Chargen-Schwankungen<\/strong><\/td><td>Growth factor composition varies between lots; IC50 shifts, differentiation efficiency changes<\/td><td>Batch reservation of FBS, or switch to hPL (pooled donors, more consistent)<\/td><\/tr>\n <tr><td><strong>Regulatory \/ GMP requirements<\/strong><\/td><td>Animal-derived raw materials require TSE\/BSE risk assessment; regulators prefer defined media<\/td><td>hPL (human-derived, GMP-grade available), rHSA + defined growth factors<\/td><\/tr>\n <tr><td><strong>Xeno-free for human cell therapy<\/strong><\/td><td>Bovine proteins can trigger immunogenic reactions in patients; not acceptable for ATMP manufacturing<\/td><td>hPL, human AB serum, rHSA, recombinant human growth factors<\/td><\/tr>\n <tr><td><strong>Defined composition for mechanistic research<\/strong><\/td><td>Unknown serum components confound interpretation of signalling experiments<\/td><td>Chemically defined serum-free medium + specific recombinant growth factors<\/td><\/tr>\n <tr><td><strong>Cost at large scale<\/strong><\/td><td>10% FBS in a 200 L bioreactor is economically unviable<\/td><td>Serum-free suspension medium (CDM) + rHSA carrier<\/td><\/tr>\n <tr><td><strong>Ethical \/ 3R compliance<\/strong><\/td><td>FBS is collected from foetal bovine blood during slaughter<\/td><td>hPL, human serum (donor-consented), plant-derived or recombinant components<\/td><\/tr>\n<\/table>\n\n<div class=\"insight-box\">\n <strong>Key insight:<\/strong> Serum itself \u2014 as a concept \u2014 is not the problem. The biologically complex, growth-factor-rich environment serum provides is often exactly what cells need. Human platelet lysate (hPL) and human serum are not \"serum-free\" in the biological sense \u2014 they are serum-equivalent supplements from a human source. True serum-free means chemically defined medium with recombinant growth factors. Choose based on your actual goal, not on a blanket assumption that \"serum-free = better.\"\n<\/div>\n\n\n<h2 id=\"decision\">2. Direct Switch vs. Stepwise Adaptation \u2014 How to Decide<\/h2>\n\n<p>Not all cells need a stepwise transition. Forcing a slow adaptation on a cell line that would tolerate a direct switch wastes 3\u20134 weeks unnecessarily. Equally, switching a primary cell directly to serum-free without adaptation will often cause apoptosis within 48 hours. The decision tree is straightforward:<\/p>\n\n<div class=\"decision-grid\">\n <div class=\"decision-card go\">\n <div class=\"dc-label\">\u2713 Direct switch \u2014 safe<\/div>\n <h3>Switch immediately<\/h3>\n <ul>\n <li>Established cancer cell lines (HeLa, A549, MCF-7, HEK293T, CHO)<\/li>\n <li>Already adapted suspension lines<\/li>\n <li>Switching FBS \u2192 hPL (same concentration)<\/li>\n <li>Switching FBS \u2192 human serum (same concentration)<\/li>\n <li>Lines already tested successfully by others in the same medium<\/li>\n <\/ul>\n <\/div>\n <div class=\"decision-card slow\">\n <div class=\"dc-label\">\u26a0 Stepwise \u2014 recommended<\/div>\n <h3>Adapt gradually<\/h3>\n <ul>\n <li>Primary cells (fibroblasts, endothelial, epithelial)<\/li>\n <li>Hybridomas switching to serum-free<\/li>\n <li>MSCs, stromal cells<\/li>\n <li>Any FBS \u2192 chemically defined switch<\/li>\n <li>Adherent lines switching to suspension<\/li>\n <li>Sensitive or slow-growing lines<\/li>\n <\/ul>\n <\/div>\n <div class=\"decision-card no\">\n <div class=\"dc-label\">\u2717 May not adapt<\/div>\n <h3>High failure risk<\/h3>\n <ul>\n <li>Neurons and post-mitotic cells<\/li>\n <li>~3\u20135% of hybridoma lines<\/li>\n <li>Highly serum-dependent primary cells<\/li>\n <li>iPSC lines outside defined maintenance media<\/li>\n <li>Cells with no published serum-free protocol<\/li>\n <\/ul>\n <\/div>\n<\/div>\n\n<div class=\"note-box\">\n <strong>Rule of thumb:<\/strong> If you are switching FBS for another human-derived serum-equivalent (hPL or human AB serum) at the same concentration \u2014 try direct first. If you are switching to chemically defined serum-free medium \u2014 always go stepwise. If your cell line has never been cultured serum-free in any published protocol \u2014 verify feasibility before committing.\n<\/div>\n\n\n<h2 id=\"protocol\">3. Stepwise Adaptation Protocol \u2014 Step by Step<\/h2>\n\n<p>The stepwise protocol below applies to: any adherent cell line transitioning to chemically defined serum-free medium, hybridomas, MSCs, and primary cells. For FBS \u2192 hPL transitions, compress the timeline to 2\u20134 passages at matching concentration before reducing.<\/p>\n\n<div class=\"steps\">\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Baseline characterisation (before you start)<\/h3>\n <p>Document your cell line's current doubling time, morphology, viability at passage, and any assay-specific performance metrics (IC50, transfection efficiency, marker expression). This is your reference \u2014 you cannot evaluate adaptation success without it. Freeze down at least 3 vials of early-passage cells before starting. If adaptation fails, you need to restart from here.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 1\u20132: 75% FBS \/ 25% target medium<\/h3>\n <p>Replace 25% of your standard FBS medium volume with the target serum-free or alternative medium. Cells are exposed to the new environment gradually while retaining 75% of their normal support. Monitor viability and doubling time. If viability drops below 80% within 48 h \u2014 slow down. If cells maintain >90% viability and normal morphology \u2014 proceed.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 3\u20134: 50% \/ 50%<\/h3>\n <p>Equal mix of standard and target medium. This is often the most critical step \u2014 cells that will fail adaptation frequently show signs here: rounding, detachment, reduced proliferation. Allow 2 full passages at this ratio. If doubling time increases by more than 50% compared to baseline \u2014 pause and assess before proceeding. Consider adding ROCK inhibitor (Y-27632, 10 \u00b5M) for sensitive adherent cells during this step to reduce anoikis.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 5\u20136: 25% FBS \/ 75% target medium<\/h3>\n <p>Final approach. At this stage, most cells that will adapt have already made the metabolic adjustment. The remaining FBS provides a residual survival signal that is now withdrawn almost completely. Monitor closely: if viability is stable at >85% and morphology is normal \u2014 you are close. If not \u2014 hold at this ratio for 1\u20132 additional passages before proceeding.<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Passage 7+: 100% target medium<\/h3>\n <p>Full transition. Allow 3\u20135 passages to stabilise before using cells for experiments. Re-measure your baseline metrics: doubling time, viability, assay performance. If all metrics are within 20% of the FBS baseline \u2014 adaptation is successful. Freeze down adapted cells in new cryoprotective medium appropriate for the target medium (hPL-based or serum-free freezing medium).<\/p>\n <\/div>\n <\/div>\n\n <div class=\"step\">\n <div class=\"step-num\"><\/div>\n <div class=\"step-body\">\n <h3>Validation<\/h3>\n <p>Run your key assay (cytotoxicity, transfection, differentiation, migration) in adapted vs. original FBS conditions. Document: doubling time, viability at passage, morphology, and assay-specific endpoint. This validation is required before switching any production workflow \u2014 and is the data package that justifies the transition to QA\/regulatory stakeholders.<\/p>\n <\/div>\n <\/div>\n\n<\/div>\n\n\n<div style=\"background:linear-gradient(135deg,#1a2e35 0%,#2e4a54 100%);border-radius:12px;padding:32px 36px;margin:32px 0;\">\n <div style=\"font-size:11px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;color:#18b7b2;margin-bottom:10px;\">Critical Tool for Adaptation Monitoring<\/div>\n <h3 style=\"color:#ffffff;font-size:20px;margin:0 0 12px;\">zenCELL owl \u2014 Continuous Incubator Monitoring During Adaptation<\/h3>\n <p style=\"color:rgba(255,255,255,0.88);font-size:15px;margin-bottom:10px;\">Serum-free adaptation fails quietly. Confluence drops by 5% overnight. Cells round slightly over a weekend. Doubling time increases by 2 hours \u2014 and by Monday, you have lost the passage. The zenCELL owl live cell imager sits inside your CO\u2082 incubator and captures brightfield images of all 24 wells continuously, at intervals as short as 1 minute.<\/p>\n <p style=\"color:rgba(255,255,255,0.88);font-size:15px;margin-bottom:16px;\">During each adaptation step, the owl tracks confluence in real time and generates an alert when confluence falls below your defined threshold \u2014 whether you are in the lab, at home, or over a bank holiday. You see exactly when and how fast your cells respond to each medium change. No guesswork. No lost weeks.<\/p>\n <div style=\"display:flex;flex-wrap:wrap;gap:10px;margin-bottom:24px;\">\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Confluence alerts<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">24 Wells gleichzeitig<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Label-free brightfield<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Kinetic time-lapse per passage<\/span>\n <span style=\"background:rgba(24,183,178,0.2);border:1px solid rgba(24,183,178,0.4);color:#18b7b2;font-size:13px;font-weight:600;padding:5px 14px;border-radius:20px;\">Weekend & night monitoring<\/span>\n <\/div>\n <a href=\"https:\/\/www.zencellowl.com\" target=\"_blank\" rel=\"noopener\" style=\"background:#18b7b2;color:#ffffff;padding:12px 28px;border-radius:50px;font-size:13px;font-weight:700;letter-spacing:0.5px;text-decoration:none;\">Erfahren Sie mehr \u00fcber zenCELL owl \u2192<\/a>\n<\/div>\n\n<div class=\"param-grid\">\n <div class=\"param-card\"><div class=\"param-label\">Typical timeline<\/div><div class=\"param-value\">3\u20136 weeks<\/div><div class=\"param-note\">7+ passages at 3\u20134 day intervals<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Step size<\/div><div class=\"param-value\">25%<\/div><div class=\"param-note\">Per passage; slower for primary cells<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Viability threshold<\/div><div class=\"param-value\">>85%<\/div><div class=\"param-note\">Minimum to proceed to next step<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Freeze backup<\/div><div class=\"param-value\">Before start<\/div><div class=\"param-note\">Minimum 3 vials pre-adaptation<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Stabilisation<\/div><div class=\"param-value\">3\u20135 passages<\/div><div class=\"param-note\">After full switch before experiments<\/div><\/div>\n <div class=\"param-card\"><div class=\"param-label\">Failure rate<\/div><div class=\"param-value\">3\u20135%<\/div><div class=\"param-note\">Of all cell lines; higher for primary<\/div><\/div>\n<\/div>\n\n\n<h2 id=\"alternatives\">4. FBS Alternatives \u2014 hPL, Human Serum, rHSA & Recombinant Components<\/h2>\n\n<p>The best alternative depends on your cell type and goal. Below are all options SeamlessBio supplies, with honest assessments of where each works well and where it does not.<\/p>\n\n<div class=\"alt-grid\">\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: MSC, primary human cells, ATMP<\/div>\n <h3>Lysat aus menschlichen Blutpl\u00e4ttchen (hPL)<\/h3>\n <p>Produced by freeze-thaw lysis of human platelets, releasing a concentrated cocktail of growth factors (PDGF, TGF-\u03b2, bFGF, VEGF, EGF, IGF-1) into plasma. Biologically richer than FBS for most human cell types \u2014 especially MSCs, where hPL at 5% outperforms FBS at 10% for proliferation rate. Xeno-free, human-derived, GMP-grade formulations available.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310% in standard basal medium<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\">View Human Serum & hPL portfolio \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Immunoassays, hybridoma, human-specific protocols<\/div>\n <h3>Human AB Serum<\/h3>\n <p>Whole human serum from AB blood group donors \u2014 the universal serum type that avoids ABO antibody interference. Provides species-matched growth factors for human cell lines, eliminates bovine protein contamination, and is directly substitutable for FBS in many protocols at the same concentration. Essential for hybridoma mAb production where bovine IgG co-purification must be avoided, and for any assay involving human immune cells.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310% (same as FBS); direct switch for many human lines<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\">View Human AB Serum \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Serum-free formulation, carrier function, AAV\/bioreactor<\/div>\n <h3>rHSA \u2014 Recombinant Human Serum Albumin<\/h3>\n <p>Albumin accounts for ~60% of total serum protein and provides the carrier function critical for fatty acid delivery, drug solubilisation, and reactive oxygen species scavenging. rHSA (rice-expressed, \u226595% purity) replaces this function in serum-free media without introducing undefined growth factors or animal-derived components. Used in serum-free viral vector production, bioreactor culture, and as a stabiliser in cryopreservation media.<\/p>\n <span class=\"alt-conc\">Typical: 1\u20135 g\/L in serum-free medium<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/albuminproteine\/\">View rHSA \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Iron delivery in serum-free medium<\/div>\n <h3>Recombinant Human Transferrin (OsrhTF)<\/h3>\n <p>Transferrin is the primary iron carrier in serum \u2014 essential for haem synthesis, electron transport and cell proliferation. In serum-free medium, cells become iron-limited within 48\u201372 h without a transferrin source. OsrhTF (rice-expressed, \u226599% purity) provides this function in a defined, animal-free format. Critical component in serum-free media for AAV production, iPSC culture and cultured meat applications.<\/p>\n <span class=\"alt-conc\">Typical: 5\u201310 \u00b5g\/mL in serum-free medium<\/span><br>\n <a href=\"https:\/\/shop.seamlessbio.de\/products\/recombinant-human-transferrin-osrhtf\">View OsrhTF \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Blocking, drug solubilisation, assay buffers<\/div>\n <h3>BSA \u2013 Rinderserumalbumin<\/h3>\n <p>BSA is the most widely used serum protein replacement for applications where only the carrier function is needed \u2014 not the full growth factor complex. Used in ELISA blocking, antibody dilution buffers, drug solubilisation, and as a low-cost albumin source in serum-free cell culture medium. Fatty acid-free grade available for receptor and lipid studies.<\/p>\n <span class=\"alt-conc\">Typical: 1\u20136 mg\/mL in serum-free medium or assay buffer<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/bsa\/\">BSA anzeigen \u2192<\/a>\n <\/div>\n\n <div class=\"alt-card\">\n <div class=\"alt-label\">Best for: Chemically defined, mechanistic studies<\/div>\n <h3>Recombinant Growth Factor Cocktails<\/h3>\n <p>For fully defined serum-free conditions, FBS function must be replaced component by component: rIGF-1 (50\u2013100 ng\/mL), rEGF (10\u201320 ng\/mL), rFGF-2 (10 ng\/mL), rInsulin (10 \u00b5g\/mL), rTransferrin (5\u201310 \u00b5g\/mL), Selenium (5 ng\/mL), and rHSA (1\u20132 g\/L) as carrier. This approach gives maximum control over the signalling environment but requires optimisation per cell type and is expensive at scale.<\/p>\n <span class=\"alt-conc\">Cell-type specific; optimise per application<\/span><br>\n <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">Contact us for component sourcing \u2192<\/a>\n <\/div>\n\n<\/div>\n\n\n<h2 id=\"comparison\">5. Full Comparison: FBS vs. All Alternatives<\/h2>\n\n<table class=\"spec-table\">\n <tr>\n <th>Supplement<\/th>\n <th>Herkunft<\/th>\n <th>Defined?<\/th>\n <th>Xeno-free?<\/th>\n <th>GMP-grade?<\/th>\n <th>Lot consistency<\/th>\n <th>Am besten geeignet f\u00fcr<\/th>\n <\/tr>\n <tr>\n <td><strong>FBS-Standard<\/strong><\/td>\n <td>Bovine foetal<\/td>\n <td>Nein<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Medium (lot-tested)<\/td>\n <td>General research, most cell lines<\/td>\n <\/tr>\n <tr>\n <td><strong>FBS, endotoxinarme<\/strong><\/td>\n <td>Bovine foetal<\/td>\n <td>Nein<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Mittel<\/td>\n <td>Cytokine assays, AAV, drug screening<\/td>\n <\/tr>\n <tr>\n <td><strong>Human AB Serum<\/strong><\/td>\n <td>Human donor<\/td>\n <td>Nein<\/td>\n <td>Ja<\/td>\n <td>Teilweise<\/td>\n <td>Medium (pooled)<\/td>\n <td>Human cell lines, hybridoma, immune assays<\/td>\n <\/tr>\n <tr>\n <td><strong>hPL (Human Platelet Lysate)<\/strong><\/td>\n <td>Human platelets<\/td>\n <td>Nein<\/td>\n <td>Ja<\/td>\n <td>Yes (GMP-grade available)<\/td>\n <td>High (pooled, standardised)<\/td>\n <td>MSC, primary human cells, ATMP manufacturing<\/td>\n <\/tr>\n <tr>\n <td><strong>rHSA<\/strong><\/td>\n <td>Recombinant (rice)<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Serum-free carrier function, bioreactor, AAV<\/td>\n <\/tr>\n <tr>\n <td><strong>OsrhTF (Recombinant Transferrin)<\/strong><\/td>\n <td>Recombinant (rice)<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Iron delivery in serum-free medium<\/td>\n <\/tr>\n <tr>\n <td><strong>BSA Fatty Acid Free<\/strong><\/td>\n <td>Rinder<\/td>\n <td>Teilweise<\/td>\n <td>Nein<\/td>\n <td>Teilweise<\/td>\n <td>Hoch<\/td>\n <td>IVF, assay buffers, blocking<\/td>\n <\/tr>\n <tr>\n <td><strong>Defined growth factor cocktail<\/strong><\/td>\n <td>Recombinant<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Ja<\/td>\n <td>Sehr hoch<\/td>\n <td>Mechanistic research, iPSC, defined protocols<\/td>\n <\/tr>\n<\/table>\n\n\n<h2 id=\"celltype\">6. Cell-Type Specific Recommendations<\/h2>\n\n<table class=\"spec-table\">\n <tr><th>Zelltyp<\/th><th>Recommended Alternative<\/th><th>Direct or Stepwise?<\/th><th>Anmerkungen<\/th><\/tr>\n <tr><td>MSC (bone marrow, adipose)<\/td><td>hPL 5%<\/td><td>Direct or 2-step<\/td><td>hPL outperforms FBS for MSC proliferation; CFU-F rate often higher<\/td><\/tr>\n <tr><td>HEK293 \/ HEK293T<\/td><td>Chemically defined CDM or serum-free SFM<\/td><td>Stepwise (4\u20136 passages)<\/td><td>Suspension adaptation required; HEK293 adapts well, HEK293T less predictably<\/td><\/tr>\n <tr><td>CHO<\/td><td>Chemically defined CDM (CD CHO, BalanCD)<\/td><td>Stepwise<\/td><td>Industry standard; most CHO lines have published serum-free protocols<\/td><\/tr>\n <tr><td>Primary human fibroblasts<\/td><td>hPL 5\u201310%<\/td><td>Direct or 2-step<\/td><td>Human-derived growth factors superior for human primary cells<\/td><\/tr>\n <tr><td>HUVEC \/ endothelial<\/td><td>Human AB Serum 5\u201310% or hPL 5%<\/td><td>Direct<\/td><td>EGM-2 serum-free media also available commercially<\/td><\/tr>\n <tr><td>Hybridom<\/td><td>Serum-free hybridoma SFM, stepwise<\/td><td>Stepwise (8 passages)<\/td><td>3\u20135% failure rate; hPL not recommended for hybridoma (IgG contamination)<\/td><\/tr>\n <tr><td>iPSC \/ hPSC<\/td><td>mTeSR1 \/ TeSR-E8 \/ HiDef-B8 (serum-free)<\/td><td>Direct (switch medium)<\/td><td>Already serum-free in maintenance; FBS only in reprogramming and some differentiation<\/td><\/tr>\n <tr><td>Vero \/ BHK \/ MDCK<\/td><td>VP-SFM, Optipro SFM or CDM<\/td><td>Stepwise<\/td><td>Used in vaccine production; regulatory preference for serum-free<\/td><\/tr>\n <tr><td>Muscle satellite cells (cultured meat)<\/td><td>rHSA + rIGF-1 + rFGF-2 + OsrhTF<\/td><td>Stepwise<\/td><td>Most challenging; still active research area<\/td><\/tr>\n <tr><td>Cancer cell lines (HeLa, A549, MCF-7)<\/td><td>Human AB Serum or hPL at same %<\/td><td>Direct<\/td><td>Most tolerate direct switch; validate assay performance<\/td><\/tr>\n<\/table>\n\n\n<h2 id=\"troubleshooting\">7. Troubleshooting Failed Adaptations<\/h2>\n\n<table class=\"spec-table\">\n <tr><th>Problem<\/th><th>Most likely cause<\/th><th>L\u00f6sung<\/th><\/tr>\n <tr><td>Cells detach and die within 48 h of switch<\/td><td>Missing attachment factors (fibronectin, vitronectin) normally supplied by FBS<\/td><td>Pre-coat flasks with fibronectin (10 \u00b5g\/mL) or vitronectin; add rHSA as attachment carrier<\/td><\/tr>\n <tr><td>Cells survive but stop proliferating<\/td><td>Missing growth factors \u2014 IGF-1, EGF or FGF typically rate-limiting<\/td><td>Add rIGF-1 (50 ng\/mL) and rEGF (20 ng\/mL) to serum-free medium; optimise stepwise<\/td><\/tr>\n <tr><td>Progressive viability loss over passages<\/td><td>Iron deficiency \u2014 transferrin function not replaced<\/td><td>Add recombinant transferrin (OsrhTF, 5\u201310 \u00b5g\/mL) or iron-saturated transferrin<\/td><\/tr>\n <tr><td>Cells aggregate in suspension<\/td><td>Absence of anti-clumping agents or shear stress from agitation<\/td><td>Add anti-clumping agent (0.1% methylcellulose or proprietary); optimise agitation speed<\/td><\/tr>\n <tr><td>Phenotypic drift after adaptation<\/td><td>Growth factor pressure selects for a subpopulation; or stress-induced epigenetic changes<\/td><td>Re-thaw from pre-adaptation stock; validate markers; consider less aggressive adaptation<\/td><\/tr>\n <tr><td>Adaptation successful but assay performance changes<\/td><td>Serum components were part of the assay readout (e.g. albumin binding, complement activity)<\/td><td>Recalibrate assay controls; run side-by-side comparison; adjust compound concentrations<\/td><\/tr>\n <tr><td>hPL causes clot\/gel formation in flask<\/td><td>Residual fibrinogen in hPL activating clotting cascade<\/td><td>Switch to heparin-free (fibrinogen-depleted) hPL formulation; add heparin (2 U\/mL) if using standard hPL<\/td><\/tr>\n<\/table>\n\n\n<h2 id=\"faq\">8. H\u00e4ufig gestellte Fragen<\/h2>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Is serum-free always better than serum-containing medium?<\/div>\n <p class=\"faq-a\">No \u2014 this is one of the most common misconceptions in cell biology. Serum provides a complex, biologically relevant environment that many cells \u2014 especially primary cells \u2014 genuinely require. Serum-free media can reduce variability and improve regulatory compliance, but they often require optimisation per cell type and can alter phenotype or assay sensitivity. The correct question is not \"serum vs. serum-free\" but \"which supplement gives the most consistent, biologically appropriate, and application-suitable result for my specific cell type and goal?\"<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Can I switch FBS directly for human serum or hPL?<\/div>\n <p class=\"faq-a\">For most established human cell lines \u2014 yes. Human AB serum and hPL are biologically equivalent to FBS in terms of growth support, and for human cells they are often superior. Start with a direct switch at the same concentration (10% hPL or human AB serum replacing 10% FBS). If viability and doubling time are maintained after 2\u20133 passages, adaptation is successful. A stepwise transition is rarely necessary for this specific switch.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">What is human platelet lysate (hPL) and how does it compare to FBS?<\/div>\n <p class=\"faq-a\">hPL is produced by freeze-thaw lysis of human platelets, releasing a concentrated pool of growth factors including PDGF, TGF-\u03b2, bFGF, VEGF, EGF and IGF-1. For human cell types \u2014 particularly MSCs, fibroblasts and other primary human cells \u2014 hPL at 5% is frequently superior to FBS at 10% in terms of proliferation rate and maintenance of phenotypic characteristics. It is xeno-free, human-derived, and GMP-grade formulations are available for ATMP manufacturing. Its main limitations are: requires heparin addition to prevent clotting (or use heparin-free\/fibrinogen-depleted hPL), lot-to-lot variability remains (though lower than FBS with large pooling), and it is not suitable for hybridoma culture (introduces human IgG that co-purifies with murine mAb).<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">What does recombinant human transferrin (OsrhTF) do in serum-free medium?<\/div>\n <p class=\"faq-a\">Transferrin is the primary iron delivery protein in serum. It binds iron in circulation and delivers it to cells via transferrin receptor-mediated endocytosis \u2014 triggering receptor recycling and intracellular iron release. Without a transferrin source in serum-free medium, cells become iron-limited within 48\u201372 hours and show reduced proliferation, mitochondrial dysfunction, and eventual apoptosis. OsrhTF (rice-expressed, \u226599% purity) is used at 5\u201310 \u00b5g\/mL in serum-free medium to replace this function. It is animal-free, defined, and fully recombinant \u2014 compatible with GMP and ATMP applications.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">How long does serum-free adaptation take?<\/div>\n <p class=\"faq-a\">For established cancer cell lines switching from FBS to human serum or hPL: often 1\u20133 passages (1\u20132 weeks). For stepwise transition to chemically defined serum-free medium: typically 7\u201310 passages (3\u20136 weeks) using 25% incremental reduction per 2 passages. For suspension adaptation of adherent lines (e.g. HEK293 for bioreactor production): 4\u20138 weeks including suspension adaptation and performance validation. Always allow 3\u20135 additional passages after the final switch before using cells for experiments, to ensure phenotypic stability.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Should I add ROCK inhibitor during serum-free adaptation?<\/div>\n <p class=\"faq-a\">Yes \u2014 for sensitive adherent cell types (primary cells, iPSC-derived cells, some hybridomas during adaptation), adding Y-27632 (ROCK inhibitor, 10 \u00b5M) during the 48\u201372 h immediately after each medium change significantly reduces anoikis (detachment-induced apoptosis). This is particularly useful at the 50% and 75% serum-free stages where anoikis risk is highest. Remove Y-27632 after the adaptation period \u2014 do not use it permanently as it can alter cytoskeletal organisation and migration phenotype.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Can rHSA replace BSA in cell culture medium?<\/div>\n <p class=\"faq-a\">Yes \u2014 rHSA (recombinant human serum albumin) can replace BSA in most serum-free cell culture applications where albumin is used as a carrier, stabiliser or fatty acid source. rHSA is human-sequence albumin expressed in rice, is animal-free, and has higher lot-to-lot consistency than BSA (which is bovine-derived). For GMP and xeno-free applications, rHSA is the preferred choice. For cost-sensitive non-GMP research applications, BSA remains widely used due to price advantage.<\/p>\n<\/div>\n\n<div class=\"faq-item\">\n <div class=\"faq-q\">Which cells cannot be adapted to serum-free conditions?<\/div>\n <p class=\"faq-a\">Post-mitotic neurons and terminally differentiated cells typically cannot be maintained serum-free without highly specialised neuronal media (e.g. Neurobasal + B27). Approximately 3\u20135% of hybridoma lines fail serum-free adaptation regardless of protocol \u2014 use FBS Ultra Low IgG as the alternative in these cases. Highly serum-dependent primary cells (some hepatocyte preparations, some smooth muscle cells) may require serum at low concentrations (<2%) permanently. If a cell type has no published serum-free protocol in PubMed, expect significant optimisation time before achieving equivalent performance.<\/p>\n<\/div>\n\n\n<div class=\"related-box\">\n <h3 class=\"related-title\">Verwandte Anwendungen und Produkte<\/h3>\n <div class=\"related-grid\">\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\" class=\"related-link\">\u2192 Human AB Serum \u2014 Mixed Donors & Type AB<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/albuminproteine\/\" class=\"related-link\">\u2192 rHSA \u2014 Recombinant Human Serum Albumin<\/a>\n <a href=\"https:\/\/shop.seamlessbio.de\/products\/recombinant-human-transferrin-osrhtf\" class=\"related-link\">\u2192 OsrhTF \u2014 Recombinant Human Transferrin<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/bsa\/\" class=\"related-link\">\u2192 BSA \u2014 Standard, Low Endotoxin, Fatty Acid Free<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/ipsc-stem-cell-culture\/\" class=\"related-link\">\u2192 iPSC & Stem Cell Culture \u2014 Medium Guide<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/aav-viral-vector-production\/\" class=\"related-link\">\u2192 AAV Viral Vector Production \u2014 Serum Strategy<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/hybridoma-monoclonal-antibody-production\/\" class=\"related-link\">\u2192 Hybridoma & mAb Production \u2014 Low IgG FBS Guide<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/fotales-rinderserum\/\" class=\"related-link\">\u2192 FBS Portfolio \u2014 All Grades<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/uberwachung-lebender-zellen\/\" class=\"related-link\">\u2192 Live Cell Monitoring \u2014 zenCELL owl Guide<\/a>\n <a href=\"https:\/\/www.zencellowl.com\" class=\"related-link\">\u2192 zenCELL-Eule-Website<\/a>\n <\/div>\n<\/div>\n\n<div class=\"back-link-wrap\">\n <a href=\"https:\/\/seamlessbio.de\/de\/anwendungen\/\" class=\"back-link\">\u2190 \u00dcbersicht \u00fcber alle Anwendungsleitf\u00e4den<\/a>\n<\/div>\n\n\n<div class=\"cta-box\">\n <h2 class=\"cta-title\">Sample Set for Serum-Free Transition<\/h2>\n <p class=\"cta-text\">Request test volumes of Human AB Serum, rHSA and OsrhTF alongside your current FBS lot \u2014 run your own side-by-side comparison before committing to a transition.<\/p>\n <p class=\"cta-contact\">E-Mail: info@seamlessbio.de | +49 851 37932226 | <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">seamlessbio.de\/kontakt<\/a><\/p>\n <div class=\"cta-buttons\">\n <a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"cta-btn-primary\">REQUEST SAMPLE SET<\/a>\n <a href=\"https:\/\/seamlessbio.de\/de\/produkte\/menschliches-serum\/\" class=\"cta-btn-outline\">HUMAN SERUM PORTFOLIO \u2192<\/a>\n <\/div>\n<\/div>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives | SeamlessBio Protocol Guide \u00b7 Serum Strategy Serum-Free Cell Culture \u2014 Adaptation Protocol & FBS Alternatives When to go stepwise, when […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-2736","page","type-page","status-publish","hentry"],"yoast_head":"\n<title>Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio<\/title>\n<meta name=\"description\" content=\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serum-Free Cell Culture Guide\" \/>\n<meta property=\"og:description\" content=\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T12:14:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"14\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\",\"name\":\"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-07-17T12:14:26+00:00\",\"dateModified\":\"2026-07-17T12:14:28+00:00\",\"description\":\"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serum-Free Cell Culture Guide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\"},\"telephone\":[],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\",\"Sunday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/serum-free-cell-culture-adaptation\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"}]}<\/script>\n","yoast_head_json":{"title":"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio","description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/","og_locale":"de_DE","og_type":"article","og_title":"Serum-Free Cell Culture Guide","og_description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","og_url":"https:\/\/seamlessbio.de\/de\/serum-free-cell-culture-adaptation\/","og_site_name":"SeamlessBio","article_modified_time":"2026-07-17T12:14:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"14\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/","url":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/","name":"Serum-Free Cell Culture \u2014 Adaptation Protocol & Alternatives | SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-07-17T12:14:26+00:00","dateModified":"2026-07-17T12:14:28+00:00","description":"Complete guide to serum-free cell culture adaptation: stepwise FBS reduction, hPL, human serum, rHSA & recombinant alternatives \u2014 expert protocol from SeamlessBio.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Serum-Free Cell Culture Guide"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo"},"telephone":[],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday","Sunday"],"opens":"09:00","closes":"17:00"}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/serum-free-cell-culture-adaptation\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=2736"}],"version-history":[{"count":5,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736\/revisions"}],"predecessor-version":[{"id":2741,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2736\/revisions\/2741"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=2736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}